Alpha Cognition Inc ((ACOG)) has held its Q3 earnings call. Read on for the main highlights of the call.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest earnings call from Alpha Cognition Inc. painted a picture of strong positive momentum, driven by significant growth in ZUNVEYL sales and increased market engagement. The company is supported by a robust financial position, although it faces challenges such as operating losses and limited payer coverage.
Sales Growth of ZUNVEYL
The third quarter of 2025 was marked by a remarkable increase in sales for ZUNVEYL. Ex-factory purchases rose by 44% quarter-over-quarter, while demand sales bottles dispensed grew by an impressive 102% from the previous quarter. This surge underscores the growing market acceptance and demand for ZUNVEYL.
Successful Engagement in Long-Term Care Market
Alpha Cognition made significant strides in the long-term care market, engaging with 2,038 homes in Q3, bringing their total reach to 2,942 unique homes. Notably, 70% of these homes placed repeat orders, highlighting the product’s acceptance and potential for sustained growth in this sector.
Positive Clinical Feedback
ZUNVEYL has received positive clinical feedback, with reports indicating improvements in cognition and a low incidence of adverse events. The product maintains a low single-digit rate of gastrointestinal adverse events, which is a promising indicator of its safety profile.
Strong Financial Position
The company’s financial health is bolstered by raising $38 million in net proceeds through an equity offering. This capital infusion extends Alpha Cognition’s operational runway into 2027, providing a solid foundation for future growth initiatives.
Progress in Research and Development
Alpha Cognition is advancing its research and development efforts with plans to initiate two studies, CONVERGE and BEACON. These studies aim to further assess ZUNVEYL’s cognitive benefits and tolerability, with completion expected by late 2026.
Operating Loss
Despite the positive developments, Alpha Cognition reported an operating loss of $5.3 million for the quarter, up from $2.5 million in the same period last year. This increase is attributed to higher selling, general, and administrative (SG&A) costs.
Challenges with Payer Coverage
The company continues to face challenges in securing broader payer coverage for ZUNVEYL. Currently, only 15% of business lines cover the product without restrictions, necessitating ongoing efforts to navigate payer obstacles.
High Operating Expenses
Total operating expenses increased to $8.2 million, reflecting the higher costs associated with commercial launch activities. This rise in expenses underscores the company’s investment in expanding its market presence.
Forward-Looking Guidance
Looking ahead, Alpha Cognition anticipates continued growth in ZUNVEYL sales as they expand market access. The company expects full-year operating expenses for 2025 to be between $28 million and $30 million, a decrease from prior guidance due to cost discipline and operational efficiency. Despite the current operating loss, improvements in derivative liabilities and interest income have helped reduce the net loss to $1.3 million.
In summary, Alpha Cognition’s earnings call highlighted a strong positive trajectory, driven by robust sales growth and strategic market engagement. While challenges such as operating losses and limited payer coverage persist, the company’s solid financial position and forward-looking initiatives provide a promising outlook for future growth.